Printer Friendly

Almiria to distribute Biomira shares.

EDMONTON, Alberta and MONTREAL--(BUSINESS WIRE)--Feb. 10, 1995-- Biomira Inc. and Almiria Capital Corp. (Almiria) Friday announced that Almiria, a Montreal-based venture capital company, will distribute its 7,612,809 common shares of Biomira to its 35 shareholders, effective immediately.

Included in the distribution are 3,732,166 of such shares which were issued to Almiria pursuant to the previously-announced amalgamation of Bioalta Inc. and a subsidiary of Biomira. Today's distribution does not affect the total outstanding common shares of Biomira which remain at 22,522,537 shares.

"We are pleased to broaden our institutional shareholder base by welcoming some of Canada's largest pension funds and institutional investors as direct shareholders of Biomira, without diluting our existing shareholder base," said Biomira's President and CEO, Alex McPherson, M.D., Ph.D.

"Almiria is a venture capital corporation and the distribution of Biomira shares is a normal activity for our company and follows a pattern established with other of Almiria's investments. This transaction does not alter our commitment to Biomira.

"We are encouraged by the progress Biomira is making as it moves its products towards commercialization and we intend to continue to support Biomira financially as it moves forward," said Almiria's President, Eric E. Baker. Mr. Baker will continue as Chairman of Biomira and Mr. Robert Mee, Vice President of Almiria Capital Corp., will continue as a Director of Biomira.

Biomira is a biotechnology company developing an integrated line of products for disease management of cancer. Diagnostic products are TRUQUANT(R) radioimmunoassays, which are designed to assist in early diagnosis and Tru-Scint(R) radioimmunoimaging compounds, which identify locoregional disease.

Therapeutics products range from OVAREX(TM) therapeutic antibody kits being investigated for use in treatment of ovarian cancer, through to THERATOPE(R) therapeutic vaccines which are being investigated for use in the treatment of breast, ovarian and colorectal cancers.

CONTACT: Biomira Inc.

Jim Devaney, 403/490-2806

or

Almiria Capital Corp.

Robert Mee, 514/631-2682

INDUSTRY KEYWORD: MEDICINE MERGERS/ACQ REPEATS: New York 212-575-8822 or 800-221-2462; Boston 617-330-5311 or

80
COPYRIGHT 1995 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1995, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 10, 1995
Words:337
Previous Article:Trenton Industries Inc. -- gets commitment from Bank of Montreal.
Next Article:Clayton Homes declares quarterly dividend.
Topics:


Related Articles
Other properties received in a stock spinoff.
Biomira Inc. announces filing of preliminary prospectus for rights offering.
BIOMIRA INC. ALMIRIA CONFIRMS STAND-BY COMMITMENT.
BIOMIRA RIGHTS OFFERING RAISES $26.6 MILLION.
Biomira Receives $28.7 Million Through Warrant Transaction.
Biomira Inc. -- Almiria share distribution announced.
Building the infrastructure of resource sharing: union catalogs, distributed search, and cross-database linkage.
Control requirement in divisive "D" reorganizations.
Nurse distributes hundreds of postcards.
SLOAN CANCER VACCINE PHASE III STUDY BEGINS.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters